Avapritinib: where the agencies disagree
This page collects every recorded health technology assessment decision for one molecule across the agencies in our archive, and compares them. The comparison is the point: each agency publishes its own verdict, none publishes how that verdict sits against the others.
What the record shows
G-BA (Germany), HAS (France) and NICE (England), among others, recommended or restricted avapritinib, while AOTMIT (Poland) and SMC (Scotland) did not recommend it.
CIPM (Spain) has been harder on avapritinib than on its own caseload: it refused 5 of 6 decisive submissions here (83%), against a base rate of 63% across everything it has assessed.
Assessment has run over 5.8 years, from 11 Sep 2020 at AWMSG (Wales) to 13 Jul 2026 at SMC (Scotland).
DMC (Denmark) changed its position: recommended on 22 May 2024, not recommended by 25 Mar 2026.
No assessment is on file from PBAC (Australia) and PHARMAC (New Zealand), each among the eight highest-volume agencies here.
Not every gap is a refusal: for avapritinib, 1 submission was never made and 1 was withdrawn or terminated before a decision — an outcome set by the company rather than the assessor.
The file is active: 24 of 30 records date from 2023 or later.
7 distinct indication wordings are recorded for avapritinib by the agencies that label one in English (AWMSG, NICE and SMC).
AWMSG (Wales) was first to assess avapritinib, on 11 Sep 2020; G-BA (Germany) did not open a file until 16 Apr 2026 — a wide spread of 5.6 years between the earliest and latest system to look at it.
The record arrives in waves: 5 separate years each carry two or more decisions, spread across 7 years in total.
9 of the 11 agencies here assessed avapritinib more than once, CIPM (Spain) most often at 6 entries — repeat review is the norm for this molecule rather than the exception.
11 of the 18 agencies in this archive hold a record for avapritinib.
The full ledger for avapritinib reads 10 recommended, 9 not recommended, 3 deferred to NICE and 2 no benefit, with 6 in other categories.
Decisions on file
| Agency | Date | Indication as recorded | Outcome | Source |
|---|---|---|---|---|
| G-BA (Germany) | 7 May 2026 | Ayvakyt — benefit assessment §35a | added benefit: minor (hint) | source |
| AOTMIT (Poland) | 6 May 2026 | programu lekowego B.115 „Leczenie chorych na mastocytozy układowe (ICD-10: C96.2, C94.3, D47.0) | not recommended | source |
| DMC (Denmark) | 25 Mar 2026 | Voksne patienter med indolent systemisk mastocytose (ISM) med moderate til svære symptomer, der er utilstrækkeligt kontr… | Ikke anbefalet | source |
| CIPM (Spain) | 25 Mar 2026 | Indicaciones terapéuticas autorizadas: Ayvakyt está indicado como monoterapia para el tratamiento de pacientes adultos c… | not financed by the SNS · art. 92 d | source |
| NYE METODER (Norway) | 22 Sep 2024 | Behandling av voksne med indolent systemisk mastocytose med moderate til alvorlige symptomer som ikke er tilstrekkelig k… | decision recorded | source |
25 further decisions for avapritinib, across 11 agencies, are not shown here. They include the most recent record on file, 13 Jul 2026 from SMC (Scotland); its outcome is in the subscriber dataset. They link to 23 further source documents.
Related molecules
- ibrutinib — same ATC class L01E — Antineoplastics
- zanubrutinib — same ATC class L01E — Antineoplastics
- cabozantinib — same ATC class L01E — Antineoplastics
- selpercatinib — same ATC class L01E — Antineoplastics
- acalabrutinib — same ATC class L01E — Antineoplastics
- ribociclib — same ATC class L01E — Antineoplastics
Coverage: 30 decisions for avapritinib from 11 agencies, 2020 to 2026. Data to 7 Sep 2026. ATC class L01E — Antineoplastics. How this page is produced. Compiled by Altima Partners; queries: sales@altimapartners.co.uk.